Maurizio Ricci

Prof. Maurizio Ricci

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2007 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Paolo BlasiPaolo Blasi
Paolo Blasi
Stefano GiovagnoliStefano Giovagnoli
Stefano Giovagnoli
ASA Schoubben
A Schoubben
MRMaurizio Ricci
Maurizio Ricci
CRC Rossi
C Rossi

5 June 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Carmelo PugliaCarmelo Puglia
Carmelo Puglia
Paolo BlasiPaolo Blasi
Paolo Blasi
LRLuisa Rizza
Luisa Rizza
ASAurélie Schoubben
Aurélie Schoubben
FBFrancesco Bonina
Francesco Bonina
MRMaurizio Ricci
Maurizio Ricci

29 January 2024 in Pharmacological Research
Verified
Journal Article
Open access
MPMatteo Puccetti
Matteo Puccetti
MPMarilena Pariano
Marilena Pariano
ASAurélie Schoubben
Aurélie Schoubben
SGStefano Giovagnoli
Stefano Giovagnoli
MRMaurizio Ricci
Maurizio Ricci
The progress in human disease treatment can be greatly advanced through the implementation of nanomedicine. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug delivery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting - by virtue of nanotechnology - allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. As such, nanomedicine has the potential to transform the treatment of conditions such as cancer, genetic diseases, and chronic illnesses by facilitating precise and cell-specific drug delivery. Additionally, personalized dosage forms and wearable devices offer the ability to tailor treatment to the unique needs of each patient, thereby increasing therapeutic effectiveness and compliance. Companion diagnostics further enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The question of whether all the potential therapeutic approaches outlined here are viable alternatives to current treatments is also discussed. In general, the application of nanotechnology in the field of biomedicine may provide a strong alternative to existing treatments for several reasons. In this review, we aim to present evidence that, although in early stages, fully merging advanced technology with innovative drug delivery shows promise for successful implementation across various disease areas, including cancer and genetic or chronic diseases.

1 September 2004 in Journal of Controlled Release
Verified
Journal Article
Closed access
LPLuana Perioli
Luana Perioli
Valeria AmbrogiValeria Ambrogi
Valeria Ambrogi
FAFausta Angelici
Fausta Angelici
MRMaurizio Ricci
Maurizio Ricci
Stefano GiovagnoliStefano Giovagnoli
Stefano Giovagnoli
CRCarlo Rossi
Carlo Rossi

1 March 2004 in Journal of Controlled Release
Verified
Journal Article
Closed access
LPLuana Perioli
Luana Perioli
Valeria AmbrogiValeria Ambrogi
Valeria Ambrogi
DRDaniela Rubini
Daniela Rubini
Stefano GiovagnoliStefano Giovagnoli
Stefano Giovagnoli
MRMaurizio Ricci
Maurizio Ricci
CRCarlo Rossi
Carlo Rossi

1 May 2005 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
MRMaurizio Ricci
Maurizio Ricci
Carmelo PugliaCarmelo Puglia
Carmelo Puglia
FBFrancesco Bonina
Francesco Bonina
CGCaterina Di Giovanni
Caterina Di Giovanni
Stefano GiovagnoliStefano Giovagnoli
Stefano Giovagnoli
CRCarlo Rossi
Carlo Rossi